Market research
4596.TSE Kubota Pharmaceutical Holdings Co., Ltd
TSE JPY Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 10B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.82
Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- JP3266500002
- Market cap
- 10B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.82
About
About Kubota Pharmaceutical Holdings Co., Ltd
Kubota Pharmaceutical Holdings Co., Ltd. engages in the pharmaceutical and medical device business worldwide. The company offers eyeMO, a remote retinal monitoring device for home-based and patient self-monitoring optical coherence tomography; and a NASA high-res version OCT device. It also provides Emixustat HCI compounds for Stargardt disease indications in Phase 3 clinical trials, as well as proliferative diabetic retinopathy and diabetic macular edema in Phase 2 clinical trials. The company was founded in 2002 and is headquartered in Minato, Japan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4596.TSE discussion.
5 years, 6 months ago
Kubota Pharmaceutical Holdings Co., Ltd is currently in a long term downtrend where the price is trading 9.3% below its 200 day moving average.
From a valuation standpoint, the stock is 351.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 318.6.
Kubota Pharmaceutical Holdings Co., Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 30.0% to $-566M since the same quarter in the previous year.
Finally, its free cash flow grew by 30.1% to $-511M since the same quarter in the previous year.
Based on the above factors, Kubota Pharmaceutical Holdings Co., Ltd gets an overall score of 2/5.